Dr. Isabel P. Neuringer, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: George Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 009300252
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 547
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 355 | 38 |
| Established patient office or other outpatient visit, 30-39 minutes | 78 | 57 |
| Established patient office or other outpatient visit, 40-54 minutes | 38 | 36 |
| Test to measure rate of airflow | 28 | 23 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 111 |
| Creon (lipase/protease/amylase) Other prescribers in Boston, MA | 40 |
| Zenpep (lipase/protease/amylase) Other prescribers in Boston, MA | 24 |
| Azithromycin Other prescribers in Boston, MA | 19 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boston, MA | 17 |
| Ciprofloxacin Hcl Other prescribers in Boston, MA | 17 |
| Doxycycline Monohydrate Other prescribers in Boston, MA | 16 |
| Prednisone Other prescribers in Boston, MA | 14 |
| Kalydeco (ivacaftor) | 13 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Boston, MA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $287 in total to this clinician.
| Viatris Specialty LLC | $221 |
|---|---|
| Vertex Pharmaceuticals Incorporated | $66.05 |
| Education | $221 |
|---|---|
| Food and Beverage | $66.05 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Viatris Specialty LLC Sep 9, 2025 | Education | $221 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16,243 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.